Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Japan & Intercontinental | July 08, 2022 | July 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date July 08, 2022 · Filed July 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,381.2782 |
Ending reported balance
After 2022-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-08 · Exercise / conversion · Acquired 3,675 · Balance 103,056.2782 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022. Row 2 · 2022-07-08 · Sale · Disposed 3,675 · Balance 99,381.2782 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $35.20 · Expires 2023-05-11 | Direct | 25,725 |
Reported balance
After 2022-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-08 · Exercise / conversion · Disposed 3,675 · Balance 25,725 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2018 Filed Jul 6, 2018 20:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,800 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-011521 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 3,800 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,800 | $146.60 | $557,080.00 |
DisclosureSEC source: 0001225208-18-011521 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,683.3906 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,800 | $42.73 | $162,355.00 |
DisclosureSEC source: 0001225208-18-011521 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,483.3906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 00:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,800 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-010236 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,800 Underlying: Common Stock · 3,800 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 00:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,800 | $142.84 | $542,792.00 |
DisclosureSEC source: 0001225208-18-010236 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,587.6173 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 00:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,800 | $42.73 | $162,355.00 |
DisclosureSEC source: 0001225208-18-010236 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,387.6173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009683 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 Underlying: Common Stock · 1,650 shares Expires 2025-05-16 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 13,000 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009683 · doc4.xml · derivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2025-05-16 F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009683 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,587.6173 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 5,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009584 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,162 shares Expires 2018-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.exercise_date: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.underlying_shares: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,560 | $136.43 | $349,260.80 |
DisclosureSEC source: 0001225208-18-009584 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,262.6173 F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009584 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,822.6173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (2,950) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 555 | $138.11 | $76,651.05 |
DisclosureSEC source: 0001225208-18-009498 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,660.6173 Read SEC document |
| May 04, 2018 Filed May 8, 2018 01:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,800 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-008852 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,600 Underlying: Common Stock · 3,800 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| May 04, 2018 Filed May 8, 2018 01:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,800 | $131.93 | $501,334.00 |
DisclosureSEC source: 0001225208-18-008852 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,215.6173 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| May 04, 2018 Filed May 8, 2018 01:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,800 | $42.73 | $162,355.00 |
DisclosureSEC source: 0001225208-18-008852 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,015.6173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,800 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-007536 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,400 Underlying: Common Stock · 3,800 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,800 | $139.37 | $529,606.00 |
DisclosureSEC source: 0001225208-18-007536 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,215.6173 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,800 | $42.73 | $162,355.00 |
DisclosureSEC source: 0001225208-18-007536 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,015.6173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 00:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,800 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-006440 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,200 Underlying: Common Stock · 3,800 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 00:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,800 | $141.84 | $538,992.00 |
DisclosureSEC source: 0001225208-18-006440 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,099.9557 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 00:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,800 | $42.73 | $162,355.00 |
DisclosureSEC source: 0001225208-18-006440 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,899.9557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009781 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 14,700 | $0.00 Strike: $110.25 | $0.00 |
DisclosureSEC source: 0001225208-17-009781 · doc4.xml · derivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Underlying: Common Stock · 14,700 shares Expires 2024-05-10 F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 equal monthly installments. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009781 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,991.0375 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009627 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,037 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F3 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,478 | $110.58 | $274,017.24 |
DisclosureSEC source: 0001225208-17-009627 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,491.0375 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009627 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,969.0375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 00:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,650 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-042819 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,650 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 00:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,650 | $83.53 | $1,140,248.66 |
DisclosureSEC source: 0001225208-16-042819 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,791.5748 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.10 to $83.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 00:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,650 | $44.62 | $608,994.75 |
DisclosureSEC source: 0001225208-16-042819 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,441.5748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,650 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-041308 · doc4.xml · derivative · entry 4 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,650 Underlying: Common Stock · 13,650 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,050 | $91.27 | $1,191,096.99 |
DisclosureSEC source: 0001225208-16-041308 · doc4.xml · nonDerivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,791.5748 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F4 · price: This transaction was executed in multiple trades at prices ranging from $90.71 to $91.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 600 | $91.71 | $55,027.50 |
DisclosureSEC source: 0001225208-16-041308 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,841.5748 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F3 · price: This transaction was executed in multiple trades at prices ranging from $91.71 to $91.72. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,650 | $44.62 | $608,994.75 |
DisclosureSEC source: 0001225208-16-041308 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,441.5748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 20:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,650 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-040249 · doc4.xml · derivative · entry 4 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 Underlying: Common Stock · 13,650 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 20:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,950 | $119.75 | $1,191,479.67 |
DisclosureSEC source: 0001225208-16-040249 · doc4.xml · nonDerivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,791.5748 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.35 to $120.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 20:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,700 | $120.81 | $447,012.91 |
DisclosureSEC source: 0001225208-16-040249 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,741.5748 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F3 · price: This transaction was executed in multiple trades at prices ranging from $120.35 to $121.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 20:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,650 | $44.62 | $608,994.75 |
DisclosureSEC source: 0001225208-16-040249 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,441.5748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 20:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,650 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-038946 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,950 Underlying: Common Stock · 13,650 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 20:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,650 | $115.72 | $1,579,578.00 |
DisclosureSEC source: 0001225208-16-038946 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,791.5748 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 20:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,650 | $44.62 | $608,994.75 |
DisclosureSEC source: 0001225208-16-038946 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,441.5748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2015. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.